Type/Product Area

Terms/Details (Date)


Orthovita Inc.

Collaboration to develop products for the orthopedics market

They will use Orthovita's matrices technology with Aastrom's bone marrow-derived cells in the effort; terms were not disclosed (3/20)


Nordic Vaccine A/S* (Denmark)

Deal to develop fast-acting vaccines that provide better protection and can be delivered in various ways

ACE will apply Nordic Vaccine's non-alum adjuvants to enhance its vaccines, with initial focus on Campylobacter, the bacterium responsible for travelers' diarrhea (3/8)


Unigen Pharmaceuticals Inc.*

Agreement for the joint discovery and development of natural products that target human fat

They will equally share costs and any profits; AdipoGenix will have rights to resulting pharmaceutical products; Unigen will have rights to cosmeceutical or nutraceutical products (4/6)


InNexus Biotechnology Inc. (Canada; CDNX:IXS)

Collaboration to use Affimed's antibodies with InNexus' SuperAntibody antibody enhancement platform

InNexus will have a right to license one of Affimed's antibodies, while Affimed will have the right to license SuperAntibody technology for one antibody; either would trigger license fees, and potential milestone and royalty payments (4/10)


Iconix Pharmaceuticals Inc.*

Deal to develop solutions for studying toxicological and pharmacological properties of drugs and drug candidates

The effort will combine Affymetrix's micro-array technology with Iconix's compound reference database and analysis software; terms were not disclosed (2/7)


Integrated DNA Technologies Inc.*

IDT got nonexclusive rights to provide RNAi research products and services under Alnylam's siRNA patents

The Kreutzer-Limmer patent family covers small interfering RNAs and their use to mediate RNAi in mammalian cells; terms were not disclosed (2/28)

AlphaRx Inc.

Proprius Pharmaceuticals Inc.*

Proprius got exclusive rights except in Asia and Mexico to AlphaRx's topical NSAID, Indaflex, and backup NSAIDs

AlphaRx gets $1M up front and could receive up to $116M in milestone payments, as well as double-digit royalties on sales (4/11)

Angiogen LLC*

Microbix Biosystems Inc. (Canada; TSE:MBX)

Deal to commercialize an Angiogen technology that uses urokinase as part of a chemotherapeutic cocktail

They will jointly pursue a partner for oncology applications; Angiogen would get royalties on resulting sales; Microbix would supply urokinase used in the combination (4/4)

Aphton Corp.

Celltrion Inc.* (South Korea)

Celltrion gained additional rights to the antibodies IGN311 and IGN312 from Aphton subsidiary Igeneon AG

Celltrion, which had rights in Asia, now has rights in Europe; it also has first right of refusal on the cancer vaccine IGN101; Igeneon gets $5M up front and up to $15M in milestone payments, as well as royalties on any sales (2/7)


Undisclosed company

The unnamed company got nonexclusive rights to dipeptidyl peptidase technology from Arisaph

The patents cover the use of DPP-IV inhibitors in diabetes applications; Arisaph gets an up- front payment and potential milestone and royalty payments (2/24)

Arius Research

Genentech Inc. (NYSE:DNA)

Genentech got rights to an anticancer antibody and others in the same family

Arius gets an up-front licensing fee and could get milestone and royalty payments in the deal (3/22)


Keryx Bio-pharmaceuticals Inc. (KERX)

Keryx acquired Accumin, a diagnostic product for measuring urinary albumin

AusAm gets 200,000 Keryx shares, which were valued at about $3.7M; it also will get royalties on sales of the FDA- approved product (3/23)

AzERx Inc.*

OrthoLogic Corp. (OLGC)

OrthoLogic gets exclusive rights to Intracellular Actin Relaxing Molecules technology, including the lead candidate from the class, AZX100

AzERx gets $390,000 in cash and 1.355M OrthoLogic shares, which were valued at about $7.7M (2/24)


CepTor Corp. (OTC BB:CEPO)

Deal under which Banyan will identify biomarkers for CepTor's Myodur

Myodur is being developed for Duchenne's muscular dystrophy; terms of the deal were not disclosed (2/7)


Immusol Inc.*

Deal to develop a fully human n-CoDeR antibody for treating age- related macular degeneration and other ophthalmic disorders

Each company will bring expertise to the collaboration; they will share further costs and revenues (4/3)


Medarex Inc. (MEDX)

They expanded deal covering the creation of a commercial line for an undisclosed Medarex monoclonal antibody

Under the expansion, Biolex will use its LEX System for commercial line creation for two more Medarex antibodies; terms were not disclosed (4/11)


Genmab A/S(Denmark; CSE:GEN)

Genmab got exclusive rights to develop drugs based on a series of angiogenesis targets identified by Bionomics

Genmab got rights to 8 proteins; Bionomics gets an up-front fee, along with potential clinical and sales milestone payments, and royalties on sales (2/13)

Research and

Caprion Pharmaceuticals Inc.*

Caprion acquired a peptide, TT-232 (now CAP-232), that has completed Phase IIa trials in solid tumors

The product, developed at Biostatin, was licensed from Expergen, a technology transfer and development organization; terms were not disclosed (3/14)

BioTrove Inc.*

Blue Sky Biotech Inc.*

Collaboration to provide screening assays on previously unscreenable drug targets

BioTrove will provide screening technology and Blue Sky will provide proteins for the mass spectrometry-based high- throughputs creening program (3/20)

Biovitrum AB*

Amgen Inc. (AMGN)

Expanded deal gives Amgen worldwide rights to Biovitrum's small- molecule 11beta-HSD1 enzyme inhibitors for treating metabolic and other diseases

Amgen already had rights in the Americas, Europe and Australia; Biovitrum gets an up-front payment and potential milestone and royalty payments; it retained co-promotion rights in the Nordic region (2/13)


Vertex Pharmaceuticals Inc. (VRTX)

They will use Caprion's proteomics platform to support biomarker discovery at Vertex

Caprion's Applied BioMedicine group will use samples from Vertex studies in the effort; terms were not disclosed (3/29)


Pharmacyclics Inc. (PCYC)

Pharmacyclics acquired a number of small-molecule drug candidates for treating cancer and other diseases

Celera gets $2M up front and between 0.5M and 1M shares of Pharmacyclics stock; it also could get up to $144M in milestone payments, and royalties on resulting sales (4/10)

Cellumen Inc.*

Serologicals Corp. (SERO)

Deal to develop and sell a cytotoxicity profiling panel and services

Serologicals subsidiary Chemical International Inc. will work with Cellumen in the deal; they would jointly market resulting solutions (2/7)

Cellectis SA*

Celonic GmbH* (Germany)

Celonic got rights to use Cellectis' Meganuclease Recombination System

The technology will be used to generate I-SceI meganuclease tagged host cell lines for production of biopharmaceuticals; terms were not disclosed (2/21)


Carna Biosciences Inc.* (Japan)

Deal to develop and market annotated kinase- focused libraries targeting kinases for various pathways and diseases

The effort combines the expertise of ChemDiv in chemistry and Carna in kinase assay development and profiling; terms were not disclosed (3/30)

Biotec GmbH*

MorphoSys AG (Germany; FSE:MOR)

Deal to co-market the rapid generation of monoclonal antibodies

Each will offer the other's services to its customers; the effort includes MorphoSys unit Antibodies by Design and Chimera's Imperacer assay technology (2/20)

Chiron Corp.

AVI BioPharma Inc. (AVII)

AVI got nonexclusive rights to develop and sell antisense drugs against hepatitis C virus

Chiron gets AVI stock as an initial license payment; further terms were not disclosed (1/27)


Fovea Pharmaceuticals SA* (France)

Deal to develop and market combination drugs to treat ophthalmic diseases; also, Fovea licensed rights to preclinical drug combinations to treat diseases of the front of the eye

Fovea will fund and develop resulting drug combinations through Phase II trials and gets rights in Europe; CombinatoRx gets U.S. rights; for the license, Combinato-Rx is eligible to receive up to $20M in up-front and milestone payments and royalties on sales (1/31)

Corus PharmaInc.*

Gilead Sciences Inc. (GILD)

Gilead is investing $25M in Corus, becoming its second largest shareholder

Gilead retained an option to purchase the rest of the company, which is in Phase III trials with an inhaled antibiotic (4/12)

CyGenics Ltd.
(Australia; ASX:

Pharmacell BV* (the Netherlands)

The companies and three institutions formed a cancer collaboration named PACRIMA

They plan to develop and mobilize stem cells outside the body; grants are expected to fund most of the work (2/2)


Amylin Pharmaceuticals Inc. (AMLN)

Amylin got exclusive rights to develop glucose- dependent insulinotropic polypeptide agonists

Diabetica gets an up-front payment and up to $41M in development- and revenue-based milestone payments, as well as royalties on resulting sales (3/7)

DiaDexus Inc.*

CFD Therapeutics Inc.*

Diadexus spun out CFD, which got rights to DiaDexus' therapeutic targets and associated monoclonal antibodies

Biotechnology Value Fund LP invested in CFD, assuming majority ownership; the antibodies are directed at cancer (3/30)


Phyton Biotech Inc. (unit of DFB Pharmaceuticals Inc.*)

Phyton got rights to a long- acting growth hormone receptor antagonist for treating various conditions

DiAthegen is entitled to milestone and royalty payments in the deal; Phyton also gets certain rights to apply DiAthegen's technology to additional protein products (4/11)

EcoBiotics Ltd.*

Antisoma plc (UK; LSE:ASM)

Antisoma will evaluate and has an option to license early stage cancer compounds

Antisoma will evaluate three compounds and can license two of them; terms of the deal were not disclosed (3/7)


Almac Diagnostics Ltd.* (UK)

Companies will use their technologies for research on the molecular basis of colorectal cancer

The InterTradeIreland INNOVA Collaborative R&D program is providing up to €0.4M to help fund the collaboration (2/9)


Genta Inc. (GNTA)

Deal to use Emisphere's eligen technology to develop an oral formulation of a gallium-containing compound

Genta will fund work at Emisphere, which also could receive milestone and royalty payments in the deal (3/22)


Tm Bioscience Corp. (Canada; TSE:TMC )

Tm got a coexclusive license to patents on a biomarker related to the P450-CYP2D6 gene

Epidauros gets an up-front signing fee and royalties on any sales of P450 Tag-It tests that include the biomarker (3/14)

Epitomics Inc.*

Biocare Medical LLC*

Deal to develop reagent products for the immunohisto- chemistry clinical diagnostic market

Epitomics will supply rabbit monoclonal antibodies while Biocare will develop test kits; terms of the deal were not disclosed (2/14)

Evotec AG

Apeiron Biologics GmbH* (Austria)

Collaboration to develop small molecules for treating pain, based on a new concept

The therapeutic concept was developed at the Institute for Molecular Biotechnology in Austria; terms were not disclosed (2/14)


Biosite Inc. (BSTE)

They gained access to each other's technology to evaluate disease targets for potential diagnostic and drug products

Biosite gets access to certain targets for use in developing diagnostics; FivePrime gets Omniclonal antibodies for certain targets; terms were not disclosed (2/21)

Galapagos NV

Arthrogen BV* (the Netherlands)

Three-year deal to discover targets for gene therapy applications in rheumatoid arthritis

Galapagos could get up to €7.5M in up-front payments, R&D funding and development milestones; it also would get royalties on resulting sales (3/30)


Chiron Corp. (CHIR)

Gene-IT is providing its GenomeQuest service to Chiron

GenomeQuest is a biological sequence search tool; terms of the deal were not disclosed (2/13)


Amgen Inc. (AMGN)

They granted each other licenses related to the manufacture and use of antibodies

The deal includes a license by Amgen to Genentech's Cabilly patent family on producing immunoglobulins; terms were not disclosed (1/26)


MetaMorphix Inc.*

Deal to explore the joint commercialization of various product opportunities

The companies have had a relationship since 1994; the focus initially will be on genetic tests for livestock and companion animals (1/27)


Alnylam Pharmaceuticals Inc. (ALNY)

Alnylam got nonexclusive rights to use Gen-Probe's hybridization protection assay technology

Alnylam will use the technology in development of therapeutic RNAi molecules; terms of the deal were not disclosed (3/9)

USA Inc.*

MDM Group Inc. (PK:MDDM)

Collaboration on Immunitor's Amivax vaccine candidate against H5N1 influenza virus

MDM will focus on marketing alliances to position Amivax for commercialization; Immunitor would get sales royalties; further terms were not disclosed (3/14)


Millennium Pharmaceuticals Inc. (MLNM)

They extended for one year deal that gives Millennium access to ImmunoGen technology

Millennium got rights to test the Tumor-Activated Prodrug technology with antibodies to specific targets; the deal also includes licensing provisions (3/30)


Alnylam Pharmaceuticals Inc. (ALNY)

Alnylam got an option to exclusively license liposome delivery technology for systemic RNAi therapeutics

Inex gets option fees and could get license fees, milestone payments and royalties on resulting sales; they also will collaborate to explore liposomal formulations (3/27)


Hana Biosciences Inc. (AMEX:HBX)

Hana got worldwide rights to three cancer agents: Marqibo, sphingosomal vinorelbine and sphingosomal topotecan

Inex gets $11.5M in stock and cash up front and up to $30.5M in Hana stock as milestones are met; it also would get royalties on sales (3/17)


GeneGo Inc.*

Deal under which they are integrating technologies in the area of systems biology

Also, GeneGo is joining InforSense's Open Workflow Partner Network (4/11)

Innovata plc

CeNeS Pharmaceuticals plc (UK; AIM:CEN)

CeNeS acquired certain rights covering a synthetic method to manufacture its M6G drug

M6G is in pivotal trials for treating post- operative pain; terms of the deal were not disclosed (3/6)


DelSite Biotechnologies Inc. (subsidiary of Carrington Laboratories Inc.; CARN)

Deal to develop a process for a cell-based avian H5 influenza whole virion antigen to be incorporated in DelSite's nasal vaccine product

The deal will allow DelSite to transition from lab-scale procedures to a scalable manufacturing process in advance of initiating cGMP production; terms were not disclosed (3/1)


ImQuest Pharmaceuticals Inc.*

ImQuest got exclusive rights to the HIV inhibitor ISIS 5320

ImQuest plans to develop the oligonucleotide as a topical microbicide, particularly in the developing world; Isis would get royalties on resulting sales (4/18)


Rosetta Genomics Ltd.* (Israel)

Deal to discover and develop antisense drugs that regulate microRNAs for treating hepatocellular carcinoma

They will use Rosetta's database of miRNA genes and Isis' chemistry and antisense expertise in the effort; terms were not disclosed (2/22)



Achaogen got rights to Isis' antibiotics-related aminoglycosides program

Isis get $1.5M of Achaogen stock and potential milestone and royalty payments in the deal (1/31)

KineMed Inc.*

Forbes Medi-Tech Inc. (Canada; FMTI)

Deal to discover non- cardiovascular indications for an undisclosed small- molecule compound from Forbes

KineMed will screen the compound; Forbes will have the option to develop it in any indications; terms were not disclosed (4/11)

Lay Line

BioXell SpA* (Italy)

Deal to develop and market LLG's preclinical pain product MNAC13, a humanized monoclonal antibody

LLG gets an up-front payment and potential milestones and royalty payments; BioXell gets exclusive worldwide rights (2/13)


Tm Bioscience Corp. (Canada; TSE:TMC)

They extended deal giving Tm rights to commercialize DNA-based molecular diagnostics that operate on Luminex's xMAP platform

The multiyear expansion replaces the original deal, which expired in March (3/29)

MaxCyte Inc.*

Sangamo BioSciences Inc. (SGMO)

Deal to use MaxCyte's cell- loading system in Sangamo's HIV/CCR5 ZFP therapeutic program

Maxcyte would supply product and be entitled to clinical and commercial milestone payments; Sangamo also got an option to use MaxCyte's system for ZFP therapeutics in oncology (3/2)

MaxCyte Inc.*

Geron Corp. (GERN)

Geron got rights to use MaxCyte's cell-loading system to manufacture mRNA-loaded dendritic cell-based vaccines

The deal includes Geron's GRNVAC1 telomerase vaccine; terms were not disclosed (2/15)

Medarex Inc.

Diatos SA* (France)

Diatos acquired full European rights to DTS-201, a doxorubicin prodrug for cancer

Medarex gets an up-front payment in cash and stock, and potential milestone and royalty payments; Diatos previously had only certain rights in Europe (3/28)



Collaboration to develop and sell MethylGene's histone deacetylase inhibitors in North America, Europe and certain other markets; the deal includes the lead product, MGCD0103

MethylGene gets a $20M license fee and a $5M equity investment at a 25% premium up front, giving Pharmion a 7.8% stake in MethylGene; milestone payments to MethylGene for MGCD0103 could reach $145M and up to $100M for other HDAC inhibitors; it also would get royalties on sales; Pharmion will fund 60% of development (1/30)


Advanced Ocular Systems Ltd. (Australia; ASX:AOS)

AOS acquired U.S. patent applications covering the ocular use of anti-VEGF agents

AOS would get more than 80% of commercialization revenues; further terms were not disclosed (2/17)


Avexa Ltd.
(Australia; ASX:AVX)

Avexa got rights to a number of HIV integrase inhibitors identified from MNL's library

MNL is eligible to receive milestone and royalty payment in the deal; terms were not disclosed (2/8)



Deal to develop drugs targeting G-CSF for treating arthritis and other inflammatory diseases

Zenyth will generate antibodies to the targets from MuriGen; terms of the deal were not disclosed (2/20)

Nanosyn Inc.*

Amphora Discovery Corp.*

Nanosyn will provide chemistry-based services to Amphora for multiple targets

Nanosyn gets an up-front fee, research funding and potential milestone payments; Amphora will own resulting technology (2/22)

Novavax Inc.

Bharat Biotech International Ltd.* (India)

Deal for the rapid development of pandemic influenza vaccine for India and other south Asian markets

BBI will fund development of the virus-like particle-based vaccine; Novavax will get access to all resulting data, and would get double-digit royalties on any sales (3/6)

Optimata Ltd.*

BioLineRx Ltd.* (Israel)

Deal to apply Optimata's Virtual Patient technology to BioLineRx's BL-1020 schizophrenia candidate

They will draw upon Optimata's biomath- ematical and disease- modeling expertise in the deal; terms were not disclosed (2/9)


Cempra Pharmacecuticals Inc.*

Cempra got worldwide rights to macrolide/ketolide antibacterial patents

Optimer gets an equity position in Cempra and is entitled to milestone and royalty payments from resulting drug candidates (4/4)

Oxford Genome
Sciences Ltd.*

Biosite Inc. (BSTE)

Collaboration to evaluate protein-based disease markers for colorectal cancer

OGS will identify proteins in samples from patients, and Biosite will have rights to develop diagnostics from them; terms were not disclosed (4/4)

BioMedica plc

VIRxSYS Corp.*

VIRxSYS got rights to use viral envelope technology for gene delivery in production of its VRX496 HIV/AIDS product

Oxford BioMedica gets an up-front license fee and annual maintenance payments; it also could receive milestone royalty payments (3/10)

PharmaCell BV*
(the Netherlands)

CyGenics Ltd. (Australia; ASX:CYN)

CyGenics is acquiring a significant stake in PharmaCell through an equity investment

The move gives CyGenics access to the European markets; terms were not disclosed (4/11)

Drug Discovery

Neurocrine Biosciences Inc. (NBIX)

Pharmacopeia will produce candidates against a disease target from Neurocrine

Pharmacopeia is entitled to milestone and royalty payments from the deal, which represents an expansion of a collaboration started in 2003 (3/15)


Gilead Sciences Inc. (GILD)

Deal under which Praecis will identify lead drug candidates for an antiviral target supplied by Gilead

Each will fund its own work in the effort; Gilead has an exclusive option to license resulting lead molecules (3/21)


Serono SA (Switzerland; NYSE:SRA)

Serono will evaluate ProBioGen's human neuronal cell line for producing recombinant proteins

Terms of the deal were not disclosed (4/5)

Sciences plc*

Medical Solutions plc* (UK)

Co-marketing deal under which they will promote each other's technologies

The focus is on protein biomarkers for use in diagnostics and drug development programs (3/15)

Systems Ltd.

Egenix Inc.

Deal to co-develop a semen- based diagnostic for prostate cancer based on the human carcinoma antigen

Egenix will provide initial funding; they then will share rights for further development and commercialization (3/7)

Qiagen NV
(the Netherlands;

ActiveSight (unit of Rigaku Americas Corp.)

They entered a co-marketing deal related to protein crystallography for drug discovery

They seek to ease access to protein crystal- lization reagents and crystallographic services; terms were not disclosed (2/22)

Group plc

StemCells Inc. (STEM)

Deal under which ReNeuron will supply cell lines to Stem Cells

The agreement follows a cross-licensing deal between the companies in 2005 (4/18)


QLT Inc.

(Canada; QLTI)

Exclusive deal to develop synthetic retinoid products for treating degenerative retinal diseases

Retinagenix is entitled to a $1.5M up-front payment, along with milestone payments and a single-digit royalty on resulting sales (4/5)


Ichor Medical Systems Inc.*

Ichor got rights to use RheoSwitch technology with its electroporation technology for delivery of a gene therapy product for multiple sclerosis

Ichor also got an option to use the Rheo- Switch Therapeutic System in two additional indications; RheoGene got an option to use Ichor's TriGrid Delivery System in drug development (2/9)

Genomics Ltd.*

Asuragen Inc.*

Collaboration to develop three prostate cancer diagnostic products

Terms of the deal were not disclosed (1/20)

Holdings plc

Idenix Pharmaceuticals Inc. (IDIX)

Sareum will generate lead chemical series, which Idenix will develop into potential drugs for treating hepatitis C

Sareum is entitled to research fees and milestone payments of up $5M, plus another milestone payment if compounds advance to clinical development (2/9)


Cytogen Corp. (CYTO)

Letter of intent grants Cytogen exclusive rights in the U.S. to Soltamox, an oral liquid hormonal therapy approved for breast cancer indications

Savient would get a $2M licensing fee up front,sales-based milestone payments of up to $4M, and royalties on sales (2/8)

Selexis SA*(Switzerland)

Henogen SA* (Belgium)

Henogen gets access to Selexis technology and expertise for cell population generation and cell line development

Henogen has nonexclusive rights to use the Selexis engineered cell lines to produce proteins and antibodies for R&D and manufacturing purposes (4/11)

Senetek plc

Plethora Solutions Holdings plc(UK; AIM:PLE)

Plethora got North American rights to Invicorp, a combi- nation drug treatment for erectile dysfunction

Senetek is entitled to milestone and royalty payments; Plethora also got an option to develop the product elsewhere outside of Europe (2/21)


Invitrogen Corp. (IVGN)

Deal to develop nanocrystal reagents for use in cancer diagnostics

The initial goal is to develop an imaging agent to identify colon carcinomas requiring surgical intervention (4/11)

Genomics Inc.*

Tm Bioscience Corp. (Canada; TSE:TMC)

Tm got exclusive rights to patents for specific biomarkers related to drugs used to treat severe sepsis

Sirius gets $4M up front, which will be repaid from earnings on sales of the severe sepsis test; earnings then will be shared equally (3/20)


Biovitrum AB* (Sweden)

Deal to develop and sell Symphogen's Sym001, which is in development for treating certain blood disorders

Symphogen gets an up-front fee and poten- tial milestone payments, along with rights in the Americas; Biovitrum has rights in Europe, Russia and the Middle East (2/1)


Biovitrum AB* (Sweden)

Deal to develop and sell Syntonix's FIX:Fc, a long-acting recombinant Factor IX preclin- ical product for hemophilia B

Syntonix gets an up-front payment and equity investment from Biovitrum, which would market the product in Europe, Russia and the Middle East; Syntonix could receive milestone payments; costs and profits will be shared equally (1/23)

Targent Inc.*

Spectrum Pharmaceuticals Inc. (SPPI)

Spectrum acquired the oncology assets of Targent, including levofolinic acid, for which an NDA has been filed

Targent got 600,000 Spectrum shares, which were valued at about $3M; Targent could receive another 650,000 shares, as well as cash payments, in the deal (3/20)


Advanced Cell Technology Inc. (OTC BB:ACTC)

Advanced Cell got rights to technology for somatic cell reprogramming

Advanced Cell had gained an option to the patents in 2005; terms of the exclusive license were not disclosed (4/3)

Tripos Inc. (TRPS)

Cara Therapeutics Inc.*

Tripos will provide chemistry services to support discovery programs at Cara

The work will be done by Tripos Discovery Research Ltd. in the UK; terms were not disclosed (3/22)


Anthra Pharmaceuticals Inc.*

Valera acquired Valstar, an anthracyline derivative indicated for treating certain bladder cancers

The product has been off the market since about 2002, when Anthra went out of business; details on the acquisition were not disclosed (4/3)

Zygogen LLC*

DanioLabs Ltd.*


DanioLabs got rights to use

Zygogen's Z-Tag technology

for internal drug screening

Zygogen is entitled to license and royalty

payments under the nonexclusive deal



* Private companies are indicated with an asterisk.

# Item occurred before the time frame of this chart but was not included in the previous chart.

Unless otherwise notes, the trading symbols listed for public biotechnology companies are on the Nasdaq market.

AIM = Alternative Investment Market; AMEX = American Stock Exchange; ASX = Australian Stock Exchange; CDNX = Canadian Venture Exchange; CSE = Copenhagen Stock Exchange; FSE = Frankfurt Stock Exchange; LSE = London Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; PK = Pink Sheets; SSE = Stockholm Stock Exchange; TSE = Toronto Stock Exchange.